News Sentiment

AGIO sentiment intelligence

Agios Pharm news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 41.23 Week of 10 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+9.7% over one week, +40.0% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued?

Market Reaction

Price moving ahead of tone

71/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 9.7% Price confirming higher
Trend fit Trend active 40.0% over four weeks
Fair value 23.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 27
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 6
TradingView 5
Investing.com 4
Simply Wall Street 3
The Motley Fool 2
Moomoo 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 11
Analyst action 4
Regulatory and legal 2
Guidance 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Simply Wall Street Direct company coverage

Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued?

Agios Pharmaceuticals' stock is under scrutiny after its mitapivat drug for sickle cell disease received Priority Review from the FDA, leading to a significant 35.51% increase in its share price over 30 days. While analysts' "fair value" suggests the stock is still undervalued at

Tone
Positive 61/100
Event
Market update
Published
15 Jul 2026 19:17
Source
Simply Wall Street
Stock Titan Direct company coverage

Agios Pharmaceuticals (NASDAQ: AGIO) director reports 1,447-share equity award and 2,894 RSUs

Agios Pharmaceuticals director Jay T. Backstrom reported acquiring 1,447 shares of common stock through the vesting of restricted stock units (RSUs) on July 8, 2026. After this transaction, he directly holds 1,447 common shares and still has 2,894 RSUs outstanding. The RSUs were

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:40
Source
Stock Titan
Market source Direct company coverage

Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease

Agios Pharmaceuticals' stock (AGIO) rose 13.8% after the FDA granted Priority Review to its supplemental New Drug Application for mitapivat in sickle cell disease, setting a PDUFA goal date of November 1, 2026. This move expands on mitapivat's existing approvals and highlights Ag

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 10:40
Source
Market source
Sahm Direct company coverage

Why Is Agios Pharma Stock Soaring Tuesday?

Agios Pharmaceuticals' stock surged over 15% after the FDA accepted its supplemental New Drug Application for mitapivat in sickle cell disease with Priority Review, setting a PDUFA goal date of November 1. This positive news led several Wall Street firms, including Truist Securit

Tone
Positive 74/100
Event
Market update
Published
09 Jul 2026 00:39
Source
Sahm
The Globe and Mail Direct company coverage

AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up

Agios Pharmaceuticals (AGIO) announced that the FDA has accepted its supplemental new drug application (sNDA) for mitapivat, an oral pyruvate kinase activator, for the treatment of sickle cell disease (SCD), granting it priority review. A decision is expected by November 1, 2026.

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 15:40
Source
The Globe and Mail
Market source Direct company coverage

Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?

Agios Pharmaceuticals (AGIO) shares surged 17.7% after the FDA granted priority review to its supplemental new drug application for mitapivat to treat sickle cell disease, with a decision expected by November 1, 2026. Despite this jump, the stock carries a Zacks Rank #3 (Hold) du

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 10:29
Source
Market source
Bitget Direct company coverage

After receiving priority review designation from the FDA for its sickle cell disease treatment, Agios Pharmaceuticals, Inc. shares surged by 12.4%.

Agios Pharmaceuticals, Inc. experienced a 12.4% surge in its share price following the FDA's designation of priority review for its sickle cell disease treatment. This regulatory fast-tracking shortens the drug review timeline, potentially leading to an accelerated market launch.

Tone
Positive 94/100
Event
Regulatory and legal
Published
07 Jul 2026 23:40
Source
Bitget
TechStock² Direct company coverage

Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average target

Agios Pharmaceuticals (AGIO) saw its stock price jump 14.9% to $42.95 after the FDA granted Priority Review for its mitapivat application for sickle cell disease. This pushed the stock 9.2% above Google Finance's average 12-month target of $39.33, with a PDUFA date set for Novemb

Tone
Positive 71/100
Event
Analyst action
Published
07 Jul 2026 19:10
Source
TechStock²
StocksToTrade Direct company coverage

AGIO Stock Jumps As Mitapivat Sickle Cell Data Fuels Hype

Agios Pharmaceuticals Inc. (AGIO) saw its stock jump by over 16% due to positive 52-week Phase 3 RISE UP mitapivat data for sickle cell disease, which showed durable hemoglobin gains and a clean safety profile. This strong clinical data supports an accelerated FDA review for mita

Tone
Positive 75/100
Event
Market update
Published
07 Jul 2026 16:10
Source
StocksToTrade
Investing.com Direct company coverage

FDA accepts Agios sNDA for mitapivat in sickle cell disease

Agios Pharmaceuticals announced that the FDA has accepted its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease with a Priority Review designation, setting a PDUFA goal date of November 1, 2026. This designation shortens the review period to six months

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 12:10
Source
Investing.com
TradingView Direct company coverage

Price to sales forward of Agios Pharmaceuticals, Inc. – DUS:8AP

This article focuses on the "Price to sales forward" financial metric for Agios Pharmaceuticals, Inc. (DUS:8AP) on the Dusseldorf Stock Exchange. It appears to be a stub or a section of a larger financial data platform, indicating where this specific financial data point can be f

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:39
Source
TradingView
Stock Titan Direct company coverage

FDA puts Agios' sickle cell drug on fast track to Nov. 1 review date

The FDA has granted Priority Review to Agios Pharmaceuticals' supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease, with a PDUFA goal date of November 1, 2026. This fast-track designation, under the accelerated approval pathway, aims to address the signif

Tone
Positive 74/100
Event
Regulatory and legal
Published
07 Jul 2026 10:00
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Agios Pharmaceuticals, Inc. – MUN:8AP

This article provides a financial overview of Agios Pharmaceuticals, Inc. (MUN:8AP) on the Munich Stock Exchange, specifically focusing on its price to sales forward ratio. The page indicates no recent trades and offers various financial data, news, community forums, and forecast

Tone
Neutral 50/100
Event
Guidance
Published
07 Jul 2026 05:09
Source
TradingView
Simply Wall Street Direct company coverage

Agios Pharmaceuticals (AGIO) Could Be 8% Below Fair Value On Growth Index Shift

Agios Pharmaceuticals (AGIO) has been reclassified into several Russell growth indices following a strong recent performance in its share price. Despite this shift, the company is still considered modestly undervalued with a fair value of $40.88 against a last close of $37.58, dr

Tone
Positive 63/100
Event
Market update
Published
06 Jul 2026 11:09
Source
Simply Wall Street
Stock Traders Daily Direct company coverage

The Technical Signals Behind (AGIO) That Institutions Follow

This article analyzes Agios Pharmaceuticals Inc. (NASDAQ: AGIO), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies no resistance levels above the current price, suggesting upside potential. The piece provides AI-generated trading strategi

Tone
Positive 64/100
Event
Guidance
Published
05 Jul 2026 17:56
Source
Stock Traders Daily
TradingView Direct company coverage

Price to book forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO

The article provides financial data on Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), specifically its price to book forward metric. It also lists various financial tools and resources available on TradingView, covering markets, community features, and business solutions.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 06:10
Source
TradingView
Finviz Direct company coverage

AGIO - Agios Pharmaceuticals Inc Latest SEC Filings

This page provides the latest SEC filings for Agios Pharmaceuticals Inc (AGIO), including financial data, trading performance metrics, and key company statistics. It details market capitalization, income, sales, various ratios, analyst recommendations, and recent stock performanc

Tone
Neutral 50/100
Event
Analyst action
Published
04 Jul 2026 10:10
Source
Finviz
TradingView Direct company coverage

Price to earnings forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO

This page provides financial information for Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), specifically its price-to-earnings forward ratio. It highlights that the market is closed, with no trades, and offers various data points and resources related to the company's financials on

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 11:39
Source
TradingView
Investing.com Canada Direct company coverage

Agios Pharmaceuticals: CMO Sarah Gheuens sells $150,502 in stock By Investing.com

Sarah Gheuens, CMO of Agios Pharmaceuticals, sold 4,007 shares of company stock worth $150,502 to cover tax obligations related to restricted stock unit vesting. This transaction followed a 10b5-1 trading plan established in 2023. Gheuens simultaneously acquired 8,375 shares thro

Tone
Positive 59/100
Event
Market update
Published
02 Jul 2026 20:11
Source
Investing.com Canada